• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NOX 0.00% 7.8¢

NOXOPHARM LIMITED - Announcements

Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in... Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in the discovery and development of treatments for cancer and inflammation. The Company has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. It is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


NOX ASCO 2020 Highlights NOX66 Potential in Late-Stage CancerPRICE SENSITIVE01/06/20 download Created with Sketch. 158.71KB
NOX Listing Rule 6.22.2 Adjustment to Option Exercise Prices28/05/20 download Created with Sketch. 289.51KB
NOX Proposed issue of Securities - NOX22/05/20 download Created with Sketch. 26.96KB
NOX Despatch of Pro Rata Entitlement Offer Documents21/05/20 download Created with Sketch. 342.89KB
NOX FDA allows Veyonda Pre-IND Submission for COVID-19PRICE SENSITIVE19/05/20 download Created with Sketch. 275.91KB
NOX Noxopharm ASCO Abstracts Live14/05/20 download Created with Sketch. 233.69KB
NOX Appendix 2A13/05/20 download Created with Sketch. 293.42KB
NOX Entitlement Offer ProspectusPRICE SENSITIVE13/05/20 download Created with Sketch. 709.28KB
NOX Entitlement Offer - Letter to Optionholders13/05/20 download Created with Sketch. 414.56KB
NOX Entitlement Offer - Letter to Ineligible Shareholders13/05/20 download Created with Sketch. 383.17KB
NOX Entitlement Offer - Letter to Eligible Shareholders13/05/20 download Created with Sketch. 444.29KB
NOX Proposed issue of Securities - NOX13/05/20 download Created with Sketch. 33.27KB
NOX $7.9 Million Fully Underwritten Entitlement Offer AnnouncedPRICE SENSITIVE13/05/20 download Created with Sketch. 282.32KB
NOX Initial Director's Interest Notice - FB08/05/20 download Created with Sketch. 148.67KB
NOX Appointment of New Board Member08/05/20 download Created with Sketch. 197.39KB
NOX Trading HaltPRICE SENSITIVE07/05/20 download Created with Sketch. 262.92KB
NOX Change in substantial holding01/05/20 download Created with Sketch. 1.6MB
NOX Change in substantial holding01/05/20 download Created with Sketch. 143.59KB
NOX Noxopharm March 2020 Quarterly Report & Appendix 4CPRICE SENSITIVE30/04/20 download Created with Sketch. 447.25KB
NOX Abscopal Responses Achieved in Prostate CancerPRICE SENSITIVE30/04/20 download Created with Sketch. 172.78KB
NOX Pipeline Expands With Potential New Brain Cancer TreatmentPRICE SENSITIVE23/04/20 download Created with Sketch. 138.77KB
NOX Approval to be sought for COVID-19 Clinical Study in U.S.PRICE SENSITIVE21/04/20 download Created with Sketch. 240.02KB
NOX Receipt of cash payment for collateral sharesPRICE SENSITIVE20/04/20 download Created with Sketch. 247.13KB
NOX Noxopharm trial data to be presented at ASCO 202007/04/20 download Created with Sketch. 231.21KB
NOX Updated Noxopharm Virtual Roadshow Corporate Presentation02/04/20 download Created with Sketch. 4.29MB
NOX Noxopharm Investigating Potential COVID-19 TreatmentPRICE SENSITIVE01/04/20 download Created with Sketch. 173.54KB
NOX Noxopharm Virtual Roadshow Corporate Presentation31/03/20 download Created with Sketch. 3.74MB
NOX Initial Director's Interest Notice26/03/20 download Created with Sketch. 148.36KB
NOX Appointment of New Board Member26/03/20 download Created with Sketch. 195.26KB
NOX Veyonda Awarded First Allowed Patent ApplicationPRICE SENSITIVE17/03/20 download Created with Sketch. 261.27KB
NOX Veyonda Clinical Program Update and Guidance13/03/20 download Created with Sketch. 224.77KB
NOX LuPIN Prostate Cancer Trial Fully RecruitedPRICE SENSITIVE03/03/20 download Created with Sketch. 220.86KB
NOX Noxopharm Corporate Presentation February 202027/02/20 download Created with Sketch. 1.3MB
NOX Half Year Accounts and Chairman LetterPRICE SENSITIVE25/02/20 download Created with Sketch. 9.47MB
NOX Section 708 Certificate21/02/20 download Created with Sketch. 252.04KB
NOX Appendix 2A21/02/20 download Created with Sketch. 281.62KB
NOX FDA grants IND approval to VeyondaPRICE SENSITIVE21/02/20 download Created with Sketch. 260.61KB
NOX Termination of Convertible Loan18/02/20 download Created with Sketch. 292.03KB
NOX Section 708 Certificate18/02/20 download Created with Sketch. 252.06KB
NOX Appendix 2A18/02/20 download Created with Sketch. 284.21KB
NOX Noxopharm Alliance With GenesisCarePRICE SENSITIVE18/02/20 download Created with Sketch. 288.79KB
NOX Proposed issue of Securities - NOX14/02/20 download Created with Sketch. 25.36KB
NOX $8.1M Financing & Re-Set of Capital StructurePRICE SENSITIVE14/02/20 download Created with Sketch. 263.13KB
NOX Pronounced survival benefit in LuPIN interim trial dataPRICE SENSITIVE14/02/20 download Created with Sketch. 192.47KB
NOX Trading HaltPRICE SENSITIVE12/02/20 download Created with Sketch. 463.36KB
NOX LuPIN interim trial data to be presented at ASCO GU 202011/02/20 download Created with Sketch. 245.87KB
NOX Lapsing of Unlisted Options06/02/20 download Created with Sketch. 137.34KB
NOX Noxopharm Dec 2019 Appendix 4CPRICE SENSITIVE31/01/20 download Created with Sketch. 333.3KB
NOX Noxopharm Non-Deal Roadshow Presentation29/01/20 download Created with Sketch. 3.33MB
NOX Appendix 3B20/01/20 download Created with Sketch. 421.28KB
NOX Listing of Nyrada Inc. spin-off on ASXPRICE SENSITIVE16/01/20 download Created with Sketch. 200.37KB
NOX Becoming a substantial holder for NYR16/01/20 download Created with Sketch. 89.96KB
NOX Noxopharm Corporate Presentation15/01/20 download Created with Sketch. 1007KB
NOX Ceasing to be a substantial holder27/12/19 download Created with Sketch. 357.77KB
NOX Change of Director's Interest Notice - GK23/12/19 download Created with Sketch. 162.19KB
NOX Section 708 Certificate23/12/19 download Created with Sketch. 196.48KB
NOX Appendix 3B23/12/19 download Created with Sketch. 427.57KB
NOX DARRT-1 Clinical Data WebinarPRICE SENSITIVE20/12/19 download Created with Sketch. 239.47KB
NOX Nyrada IPO Offer Fully SubscribedPRICE SENSITIVE17/12/19 download Created with Sketch. 173.75KB
NOX Unlisted Options Expiring 18 January 202013/12/19 download Created with Sketch. 217.26KB
NOX Lodgement of Nyrada Inc Supplementary ProspectusPRICE SENSITIVE09/12/19 download Created with Sketch. 236.14KB
NOX Nyrada Inc Initial Public Offering OpensPRICE SENSITIVE04/12/19 download Created with Sketch. 225.24KB
NOX Section 708 Certificate - Notes03/12/19 download Created with Sketch. 299.77KB
NOX Section 708 Certificate03/12/19 download Created with Sketch. 179.81KB
NOX Appendix 3B03/12/19 download Created with Sketch. 428.87KB
NOX AU$2.4m Increase to Funding AgreementPRICE SENSITIVE03/12/19 download Created with Sketch. 200.88KB
NOX Section 708 Certificate03/12/19 download Created with Sketch. 161.42KB
NOX Appendix 3B03/12/19 download Created with Sketch. 428.84KB
NOX Positive DARRT-1 Data in Late-Stage Prostate CancerPRICE SENSITIVE02/12/19 download Created with Sketch. 190.84KB
NOX Trading HaltPRICE SENSITIVE28/11/19 download Created with Sketch. 302.37KB
NOX Lodgement of Nyrada Inc Prospectus - Initial Public OfferingPRICE SENSITIVE26/11/19 download Created with Sketch. 4.69MB
NOX Constitution20/11/19 download Created with Sketch. 463.82KB
NOX Updated Share Trading Policy20/11/19 download Created with Sketch. 238.54KB
NOX Results of Meeting20/11/19 download Created with Sketch. 250.06KB
NOX Noxopharm 2019 AGM Corporate Presentations20/11/19 download Created with Sketch. 15.36MB
NOX DARRT-1 Interim Data Presented To Conference12/11/19 download Created with Sketch. 865.99KB
NOX LuPIN Data Being Presented To Conference12/11/19 download Created with Sketch. 308.33KB
NOX Appointment of Chief Commercial Officer06/11/19 download Created with Sketch. 247.4KB
NOX Noxopharm October 2019 Newsletter30/10/19 download Created with Sketch. 2.43MB
NOX Appendix 4C - QuarterlyPRICE SENSITIVE30/10/19 download Created with Sketch. 331.03KB
NOX Dr Graham Kelly to Assume CEO RolePRICE SENSITIVE28/10/19 download Created with Sketch. 145.88KB
NOX Appendix 3B25/10/19 download Created with Sketch. 476.17KB
NOX Section 708 Certificate25/10/19 download Created with Sketch. 159.09KB
NOX NOX and Nyrada TechKnow Invest Roadshow Presentations22/10/19 download Created with Sketch. 5.19MB
NOX Durable Anti-Cancer Effect Confirmed in DARRT-1 StudyPRICE SENSITIVE21/10/19 download Created with Sketch. 189.2KB
NOX Notice of 2019 Annual General Meeting & Proxy Form18/10/19 download Created with Sketch. 580.36KB
NOX Potential Fundamental Change in Treatment of Brain CancerPRICE SENSITIVE18/10/19 download Created with Sketch. 151.36KB
NOX New Executive Appointments and Board Change16/10/19 download Created with Sketch. 191.96KB
NOX Final Director's Interest Notice16/10/19 download Created with Sketch. 186.26KB
NOX Noxopharm 2019 Annual General Meeting Details02/10/19 download Created with Sketch. 134.39KB
NOX FNN Interview with Graham on recent LuPIN interim data02/10/19 download Created with Sketch. 128.82KB
NOX Further Review Shows Major Clinical Benefits from VeyondaPRICE SENSITIVE30/09/19 download Created with Sketch. 178.15KB
NOX Annual Report to Shareholders26/09/19 download Created with Sketch. 2.18MB
NOX Appendix 4G26/09/19 download Created with Sketch. 233.67KB
NOX Corporate Governance Statement26/09/19 download Created with Sketch. 327.74KB
NOX Section 708 Certificate26/09/19 download Created with Sketch. 154KB
NOX Section 708 Certificate26/09/19 download Created with Sketch. 324.93KB
NOX Appendix 3B26/09/19 download Created with Sketch. 483.36KB
NOX Amended/Departure of Dr Van Wyk24/09/19 download Created with Sketch. 146.71KB
NOX Departure of Dr Wan Wyk24/09/19 download Created with Sketch. 146.71KB
NOX ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
01/06/20PRICE SENSITIVE download Created with Sketch. 158.71KB
NOX Listing Rule 6.22.2 Adjustment to Option Exercise Prices
28/05/20 download Created with Sketch. 289.51KB
NOX Proposed issue of Securities - NOX
22/05/20 download Created with Sketch. 26.96KB
NOX Despatch of Pro Rata Entitlement Offer Documents
21/05/20 download Created with Sketch. 342.89KB
NOX FDA allows Veyonda Pre-IND Submission for COVID-19
19/05/20PRICE SENSITIVE download Created with Sketch. 275.91KB
NOX Noxopharm ASCO Abstracts Live
14/05/20 download Created with Sketch. 233.69KB
NOX Appendix 2A
13/05/20 download Created with Sketch. 293.42KB
NOX Entitlement Offer Prospectus
13/05/20PRICE SENSITIVE download Created with Sketch. 709.28KB
NOX Entitlement Offer - Letter to Optionholders
13/05/20 download Created with Sketch. 414.56KB
NOX Entitlement Offer - Letter to Ineligible Shareholders
13/05/20 download Created with Sketch. 383.17KB
NOX Entitlement Offer - Letter to Eligible Shareholders
13/05/20 download Created with Sketch. 444.29KB
NOX Proposed issue of Securities - NOX
13/05/20 download Created with Sketch. 33.27KB
NOX $7.9 Million Fully Underwritten Entitlement Offer Announced
13/05/20PRICE SENSITIVE download Created with Sketch. 282.32KB
NOX Initial Director's Interest Notice - FB
08/05/20 download Created with Sketch. 148.67KB
NOX Appointment of New Board Member
08/05/20 download Created with Sketch. 197.39KB
NOX Trading Halt
07/05/20PRICE SENSITIVE download Created with Sketch. 262.92KB
NOX Change in substantial holding
01/05/20 download Created with Sketch. 1.6MB
NOX Change in substantial holding
01/05/20 download Created with Sketch. 143.59KB
NOX Noxopharm March 2020 Quarterly Report & Appendix 4C
30/04/20PRICE SENSITIVE download Created with Sketch. 447.25KB
NOX Abscopal Responses Achieved in Prostate Cancer
30/04/20PRICE SENSITIVE download Created with Sketch. 172.78KB
NOX Pipeline Expands With Potential New Brain Cancer Treatment
23/04/20PRICE SENSITIVE download Created with Sketch. 138.77KB
NOX Approval to be sought for COVID-19 Clinical Study in U.S.
21/04/20PRICE SENSITIVE download Created with Sketch. 240.02KB
NOX Receipt of cash payment for collateral shares
20/04/20PRICE SENSITIVE download Created with Sketch. 247.13KB
NOX Noxopharm trial data to be presented at ASCO 2020
07/04/20 download Created with Sketch. 231.21KB
NOX Updated Noxopharm Virtual Roadshow Corporate Presentation
02/04/20 download Created with Sketch. 4.29MB
NOX Noxopharm Investigating Potential COVID-19 Treatment
01/04/20PRICE SENSITIVE download Created with Sketch. 173.54KB
NOX Noxopharm Virtual Roadshow Corporate Presentation
31/03/20 download Created with Sketch. 3.74MB
NOX Initial Director's Interest Notice
26/03/20 download Created with Sketch. 148.36KB
NOX Appointment of New Board Member
26/03/20 download Created with Sketch. 195.26KB
NOX Veyonda Awarded First Allowed Patent Application
17/03/20PRICE SENSITIVE download Created with Sketch. 261.27KB
NOX Veyonda Clinical Program Update and Guidance
13/03/20 download Created with Sketch. 224.77KB
NOX LuPIN Prostate Cancer Trial Fully Recruited
03/03/20PRICE SENSITIVE download Created with Sketch. 220.86KB
NOX Noxopharm Corporate Presentation February 2020
27/02/20 download Created with Sketch. 1.3MB
NOX Half Year Accounts and Chairman Letter
25/02/20PRICE SENSITIVE download Created with Sketch. 9.47MB
NOX Section 708 Certificate
21/02/20 download Created with Sketch. 252.04KB
NOX Appendix 2A
21/02/20 download Created with Sketch. 281.62KB
NOX FDA grants IND approval to Veyonda
21/02/20PRICE SENSITIVE download Created with Sketch. 260.61KB
NOX Termination of Convertible Loan
18/02/20 download Created with Sketch. 292.03KB
NOX Section 708 Certificate
18/02/20 download Created with Sketch. 252.06KB
NOX Appendix 2A
18/02/20 download Created with Sketch. 284.21KB
NOX Noxopharm Alliance With GenesisCare
18/02/20PRICE SENSITIVE download Created with Sketch. 288.79KB
NOX Proposed issue of Securities - NOX
14/02/20 download Created with Sketch. 25.36KB
NOX $8.1M Financing & Re-Set of Capital Structure
14/02/20PRICE SENSITIVE download Created with Sketch. 263.13KB
NOX Pronounced survival benefit in LuPIN interim trial data
14/02/20PRICE SENSITIVE download Created with Sketch. 192.47KB
NOX Trading Halt
12/02/20PRICE SENSITIVE download Created with Sketch. 463.36KB
NOX LuPIN interim trial data to be presented at ASCO GU 2020
11/02/20 download Created with Sketch. 245.87KB
NOX Lapsing of Unlisted Options
06/02/20 download Created with Sketch. 137.34KB
NOX Noxopharm Dec 2019 Appendix 4C
31/01/20PRICE SENSITIVE download Created with Sketch. 333.3KB
NOX Noxopharm Non-Deal Roadshow Presentation
29/01/20 download Created with Sketch. 3.33MB
NOX Appendix 3B
20/01/20 download Created with Sketch. 421.28KB
NOX Listing of Nyrada Inc. spin-off on ASX
16/01/20PRICE SENSITIVE download Created with Sketch. 200.37KB
NOX Becoming a substantial holder for NYR
16/01/20 download Created with Sketch. 89.96KB
NOX Noxopharm Corporate Presentation
15/01/20 download Created with Sketch. 1007KB
NOX Ceasing to be a substantial holder
27/12/19 download Created with Sketch. 357.77KB
NOX Change of Director's Interest Notice - GK
23/12/19 download Created with Sketch. 162.19KB
NOX Section 708 Certificate
23/12/19 download Created with Sketch. 196.48KB
NOX Appendix 3B
23/12/19 download Created with Sketch. 427.57KB
NOX DARRT-1 Clinical Data Webinar
20/12/19PRICE SENSITIVE download Created with Sketch. 239.47KB
NOX Nyrada IPO Offer Fully Subscribed
17/12/19PRICE SENSITIVE download Created with Sketch. 173.75KB
NOX Unlisted Options Expiring 18 January 2020
13/12/19 download Created with Sketch. 217.26KB
NOX Lodgement of Nyrada Inc Supplementary Prospectus
09/12/19PRICE SENSITIVE download Created with Sketch. 236.14KB
NOX Nyrada Inc Initial Public Offering Opens
04/12/19PRICE SENSITIVE download Created with Sketch. 225.24KB
NOX Section 708 Certificate - Notes
03/12/19 download Created with Sketch. 299.77KB
NOX Section 708 Certificate
03/12/19 download Created with Sketch. 179.81KB
NOX Appendix 3B
03/12/19 download Created with Sketch. 428.87KB
NOX AU$2.4m Increase to Funding Agreement
03/12/19PRICE SENSITIVE download Created with Sketch. 200.88KB
NOX Section 708 Certificate
03/12/19 download Created with Sketch. 161.42KB
NOX Appendix 3B
03/12/19 download Created with Sketch. 428.84KB
NOX Positive DARRT-1 Data in Late-Stage Prostate Cancer
02/12/19PRICE SENSITIVE download Created with Sketch. 190.84KB
NOX Trading Halt
28/11/19PRICE SENSITIVE download Created with Sketch. 302.37KB
NOX Lodgement of Nyrada Inc Prospectus - Initial Public Offering
26/11/19PRICE SENSITIVE download Created with Sketch. 4.69MB
NOX Constitution
20/11/19 download Created with Sketch. 463.82KB
NOX Updated Share Trading Policy
20/11/19 download Created with Sketch. 238.54KB
NOX Results of Meeting
20/11/19 download Created with Sketch. 250.06KB
NOX Noxopharm 2019 AGM Corporate Presentations
20/11/19 download Created with Sketch. 15.36MB
NOX DARRT-1 Interim Data Presented To Conference
12/11/19 download Created with Sketch. 865.99KB
NOX LuPIN Data Being Presented To Conference
12/11/19 download Created with Sketch. 308.33KB
NOX Appointment of Chief Commercial Officer
06/11/19 download Created with Sketch. 247.4KB
NOX Noxopharm October 2019 Newsletter
30/10/19 download Created with Sketch. 2.43MB
NOX Appendix 4C - Quarterly
30/10/19PRICE SENSITIVE download Created with Sketch. 331.03KB
NOX Dr Graham Kelly to Assume CEO Role
28/10/19PRICE SENSITIVE download Created with Sketch. 145.88KB
NOX Appendix 3B
25/10/19 download Created with Sketch. 476.17KB
NOX Section 708 Certificate
25/10/19 download Created with Sketch. 159.09KB
NOX NOX and Nyrada TechKnow Invest Roadshow Presentations
22/10/19 download Created with Sketch. 5.19MB
NOX Durable Anti-Cancer Effect Confirmed in DARRT-1 Study
21/10/19PRICE SENSITIVE download Created with Sketch. 189.2KB
NOX Notice of 2019 Annual General Meeting & Proxy Form
18/10/19 download Created with Sketch. 580.36KB
NOX Potential Fundamental Change in Treatment of Brain Cancer
18/10/19PRICE SENSITIVE download Created with Sketch. 151.36KB
NOX New Executive Appointments and Board Change
16/10/19 download Created with Sketch. 191.96KB
NOX Final Director's Interest Notice
16/10/19 download Created with Sketch. 186.26KB
NOX Noxopharm 2019 Annual General Meeting Details
02/10/19 download Created with Sketch. 134.39KB
NOX FNN Interview with Graham on recent LuPIN interim data
02/10/19 download Created with Sketch. 128.82KB
NOX Further Review Shows Major Clinical Benefits from Veyonda
30/09/19PRICE SENSITIVE download Created with Sketch. 178.15KB
NOX Annual Report to Shareholders
26/09/19 download Created with Sketch. 2.18MB
NOX Appendix 4G
26/09/19 download Created with Sketch. 233.67KB
NOX Corporate Governance Statement
26/09/19 download Created with Sketch. 327.74KB
NOX Section 708 Certificate
26/09/19 download Created with Sketch. 154KB
NOX Section 708 Certificate
26/09/19 download Created with Sketch. 324.93KB
NOX Appendix 3B
26/09/19 download Created with Sketch. 483.36KB
NOX Amended/Departure of Dr Van Wyk
24/09/19 download Created with Sketch. 146.71KB
NOX Departure of Dr Wan Wyk
24/09/19 download Created with Sketch. 146.71KB
(20min delay)
Last
7.8¢
Change
0.000(0.00%)
Mkt cap ! $22.79M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 10000 6.7¢
 

Sellers (Offers)

Price($) Vol. No.
7.7¢ 10000 1
View Market Depth
Last trade - 16.12pm 16/05/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.